Who is Eligible for Ozempic for Weight Loss?

Last reviewed: July 9, 2026

Last updated: July 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Ozempic and Wegovy launched a national conversation about GLP-1 therapy for weight management, but eligibility depends on more than just wanting to lose pounds. The FDA approval framework and clinical practice guidelines establish clear thresholds, yet individual patient circumstances often determine real-world candidacy. Understanding who qualifies helps you assess whether semaglutide aligns with your health goals.

Standard BMI and Weight Loss Eligibility Requirements

Medical guidelines suggest semaglutide consideration for adults with a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher when accompanied by weight-related health conditions. BMI serves as a starting reference point because it correlates with metabolic risk and comorbidity burden in population studies. However, BMI alone does not capture muscle mass, bone density, or individual metabolic variation, which is why PlexusDx evaluates the complete clinical picture during your assessment.

Weight loss of 5–10% of baseline body weight reduces cardiovascular risk, improves blood sugar control, and can lower inflammation markers significantly. Clinical trials showed participants on semaglutide achieved average weight reductions of 15–22% over 68 weeks, substantially exceeding typical diet-and-exercise outcomes. Your specific candidacy hinges on whether your current weight and health profile suggest meaningful benefit from pharmacotherapy.

Medical Conditions That May Increase Semaglutide Eligibility

Type 2 diabetes, prediabetes, hypertension, sleep apnea, fatty liver disease, and joint pain related to excess weight all strengthen the clinical case for semaglutide therapy. Each condition reflects underlying metabolic dysfunction that GLP-1 receptor activation can help address through multiple mechanisms—reduced appetite, improved insulin sensitivity, and decreased hepatic fat accumulation. If you carry even one weight-associated comorbidity, your eligibility profile shifts from cosmetic weight loss into therapeutic territory.

Family history of early-onset cardiovascular disease or type 2 diabetes also influences candidacy, as these genetic predispositions amplify the health benefits of aggressive weight management. PlexusDx screening includes detailed questions about personal and family medical history to contextualize your BMI within your unique cardiometabolic risk landscape.

Age, Medications, and Contraindications Affecting Candidacy

Adults aged 18 and older can typically access semaglutide, though pregnancy, breastfeeding, and history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN2) represent absolute contraindications. Certain medications—particularly sulfonylureas or insulin—may require dose adjustment if combined with semaglutide due to hypoglycemia risk. Kidney or liver disease may influence dosing strategy but does not automatically disqualify candidacy if clinical benefit outweighs risk.

Gastrointestinal disorders such as gastroparesis or severe acid reflux warrant careful assessment, as GLP-1 therapy slows gastric motility and may temporarily worsen symptoms. PlexusDx clinicians review your full medication list and organ function during initial consultation to identify potential interactions or safety concerns before treatment starts.

How PlexusDx Personalized Semaglutide Determines Your Fit

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Starting at $149 per month with no membership fees, HSA/FSA eligibility, and availability across all 50 states, PlexusDx removes financial and geographic barriers to candidacy assessment. You do not need insurance approval or prior authorization—a licensed clinician reviews your health history, labs, and goals, then determines whether compounded semaglutide injection or an alternative GLP-1 formulation best suits your clinical profile.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Do I need to be obese or have diabetes to qualify for semaglutide?

No. Semaglutide eligibility includes individuals with BMI 27–29 if weight-related health conditions are present, such as hypertension, prediabetes, or sleep apnea. PlexusDx evaluates your complete medical history—not just weight—to determine whether therapy aligns with your health risks and treatment goals.

What clinical evidence supports semaglutide for weight loss in eligible patients?

Randomized controlled trials (STEP program) demonstrated that semaglutide produces average weight loss of 15–22% over 68 weeks in people with obesity or overweight with comorbidities, compared to 2–3% with placebo. Benefit extends beyond weight: participants showed improved blood pressure, blood sugar, and cardiovascular risk markers.

How much does PlexusDx compounded semaglutide cost, and do I need insurance?

PlexusDx compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan) with no membership fee or insurance requirement. Treatment is HSA/FSA eligible, and PlexusDx serves all 50 states, making candidacy purely clinical rather than insurance-dependent.

Are there side effects that might disqualify me from semaglutide therapy?

Common side effects—nausea, constipation, reduced appetite—are generally manageable and often diminish after the first few weeks. However, absolute contraindications include pregnancy, personal or family history of medullary thyroid cancer, and MEN2 syndrome. PlexusDx reviews your medical history upfront to identify safety concerns.

Can the PlexusDx Precision Peptide Genetic Test improve my treatment candidacy or outcomes?

No — the Precision Peptide Genetic Test does not predict your response to Ozempic or any specific medication. It analyzes pathway-level variants (GLP1R, and GIPR) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic
• Ozempic Weight Loss Before And After Pictures

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.